Johnson & Johnson and AstraZeneca pledged to make their vaccines available on a not-for-profit basis
The US drugmaker Pfizer and the German biotech firm BioNTech stand to bring in nearly $13bn (£9.8bn) in global sales from their coronavirus vaccine next year, which will be evenly split between the two companies, according to analysts at the US investment bank Morgan Stanley.
Pfizer’s half would be more than the US pharmaceutical group’s bestselling product, a pneumonia vaccine that generated $5.8bn last year.
Related: Pfizer and BioNTech’s vaccine poses global logistics challenge
Related: 6 key questions about the Pfizer/BioNTech Covid-19 vaccine
